Related Experiment Videos
Induction of immune responses against human papillomaviruses by hypervariable epitope constructs
K Jyotsna Reddy1, Babak Banapour, David E Anderson
1Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA 95616, USA.
Immunology
|May 19, 2004
Summary
New hypervariable epitope constructs (HECs) induce cross-reactive antibodies against human papillomaviruses (HPV). This approach may overcome type-specific immunity, advancing the development of broadly protective HPV vaccines.
Area of Science:
- Immunology
- Virology
- Vaccine Development
Background:
- Human papillomaviruses (HPV) pose a significant health challenge, with current vaccines often exhibiting type-specific immunity.
- Achieving broadly reactive antibody responses against major oncogenic HPV strains is crucial for an ideal prophylactic vaccine.
- Previous studies indicate HPV structural proteins and virus-like particles (VLPs) elicit limited cross-reactivity.
Purpose of the Study:
- To evaluate the breadth of antibody responses induced by hypervariable epitope constructs (HECs) against diverse HPV types.
- To determine if HECs can overcome the type-specific immunity typically observed with HPV vaccines.
- To assess the potential of HECs in developing broadly protective HPV prophylactic vaccines.
Main Methods:
- Mice were immunized with hypervariable epitope constructs (HECs) derived from immunodominant B-cell epitopes of HPV L1 capsid protein.
- Sera from immunized mice were tested for antibody reactivity against peptides representing analogous sequences of HPV types 16, 18, 31, and 45.
- Antibody inhibition of HPV-16 L1 VLP-mediated haemagglutination was assessed to evaluate binding to native viral capsid proteins.
Main Results:
- Antibody responses from mice immunized with HECs cross-reacted with analogues of HPV types 16 and 18.
- Antibodies generated by HEC immunization inhibited HPV-16 L1 VLP haemagglutination, indicating binding to native viral structures.
- HECs demonstrated the ability to induce antibodies with broader reactivity than previously observed with conventional HPV immunogens.
Conclusions:
- Hypervariable epitope constructs (HECs) show promise in eliciting cross-reactive antibody responses against multiple HPV types.
- HECs may represent a viable strategy to overcome the limitations of type-specific immunity in current HPV vaccines.
- Further research into HECs could lead to the development of more effective and broadly protective prophylactic HPV vaccines.